Company news

Rafael Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update

October 29, 2026

Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C

October 29, 2026

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

September 30, 2026

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

June 11, 2026

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

June 10, 2026

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

April 22, 2026

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

March 16, 2026

Quarterly Report for Quarter Ending October 31, 2025 (Form 10-Q)

December 12, 2025

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

December 11, 2025

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

October 29, 2025

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

October 28, 2025

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

September 16, 2025

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

August 27, 2025

Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data

June 18, 2025

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

June 11, 2025

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

June 4, 2025

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 20, 2025

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

April 29, 2025

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

April 24, 2025

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

March 26, 2025

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

March 13, 2025

Amendment to Annual Report (Form 10-K/A)

December 20, 2024

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

December 11, 2024

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

November 6, 2024

Decks

The 5 newest of 9 decks. Every deck is listed under its year.